截至12月31日，建发致新股东户数2.59万，较上期减少10.35%；人均流通股1949股，较上期增加 11.55%。2025年1月-9月，建发致新实现营业收入148.61亿元，同比增长10.18%；归母净利润2.30亿元， 同比增长45.01%。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 2月6日，建发致新跌0.14%，成交额5153.33万元。两融数据显示，当日建发致新获融资买入额209.38万 元，融资偿还328.63万元，融资净买入-119.25万元。截至2月6日，建发致新融资融券余额合计9970.46 万元。 融资方面，建发致新当日融资买入209.38万元。当前融资余额9970.46万元，占流通市值的6.75%。 融券方面，建发致新2月6日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，上海建发致新医疗科技集团股份有 ...

证券代码：301584 证券简称：建发致新 公告编号：2026-003 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）于近日收到公司非独立董事王文怀先生提 交的书面辞职报告，其因个人工作原因，申请辞去公司第三届董事会董事、第三届董事会战略委员会委 员职务，辞职后不再担任公司其他职务。 鉴于王文怀先生辞去公司董事职务未导致公司董事会成员低于法定最低人数，根据《中华人民共和国公 司法》《深圳证券交易所上市公司自律监管指引第2号一一创业板上市公司规范运作》及《公司章程》 等相关规定，王文怀先生的辞职不会对公司经营和董事会运作产生影响。王文怀先生的辞职报告自送达 董事会之日起生效，其原定任期至第三届董事会届满之日止。 登录新浪财经APP 搜索【信披】查看更多考评等级 上海建发致新医疗科技集团股份有限公司 关于公司董事辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特此公告。 上海建发致新医疗科技集团股份有限公司董事会 2026 年 1 月 20 日 截至本公告披露日，王文怀先生未持有公司股票，辞职后将继续履行其在公司首次公开发行股票并上市 时作出 ...

证券代码：301584 证券简称：建发致新 公告编号：2026-003 上海建发致新医疗科技集团股份有限公司 关于公司董事辞职的公告 鉴于王文怀先生辞去公司董事职务未导致公司董事会成员低于法定最低人 数，根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规定，王文怀先生的 辞职不会对公司经营和董事会运作产生影响。王文怀先生的辞职报告自送达董事 会之日起生效，其原定任期至第三届董事会届满之日止。 截至本公告披露日，王文怀先生未持有公司股票，辞职后将继续履行其在公 司首次公开发行股票并上市时作出的各项仍在履行期限内的承诺，除此之外不存 在其他应履行而未履行的承诺。同时，王文怀先生已按照《董事、高级管理人员 离职管理制度》做好离职交接工作，公司将按照相关法律法规及《公司章程》有 关规定尽快完成公司非独立董事的补选工作。 王文怀先生在公司担任董事期间，恪尽职守、勤勉尽责，公司及公司董事会 对其在任职期间为公司发展作出的贡献表示衷心感谢！ 特此公告。 上海建发致新医疗科技集团股份有限公司董事会 2026 年 1 月 20 日 本公司及董事会全体成员 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.48% on January 20, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Guofa Co., Ltd. (600538) with a closing price of 6.87, up 3.46% and a trading volume of 245,400 shares, totaling 168 million yuan [1] - Huaren Health (301408) closed at 22.08, up 1.38% with a trading volume of 317,600 shares, totaling 700 million yuan [1] - Conversely, significant decliners included: - Jianghe Pharmaceutical (002788) with a closing price of 16.64, down 6.04% and a trading volume of 872,500 shares, totaling 1.465 billion yuan [2] - Yingte Group (000411) closed at 13.84, down 2.40% with a trading volume of 230,300 shares, totaling 316 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million yuan from institutional investors and a net outflow of 109 million yuan from speculative funds, while retail investors had a net inflow of 607 million yuan [2] - Key stocks with notable capital flows included: - Huaren Health (301408) with a net inflow of 46.16 million yuan from institutional investors, but a net outflow of 48.48 million yuan from retail investors [3] - Yifeng Pharmacy (603939) had a net inflow of 21.74 million yuan from institutional investors, but also saw a net outflow of 1.63 million yuan from retail investors [3]

Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. (referred to as "Jianda Zhixin") expects a positive increase in net profit for the fiscal year 2025, with projections indicating a net profit of between 242 million to 296 million yuan, representing a year-on-year growth of 6.00% to 29.65% [1] Group 1 - The expected net profit attributable to shareholders is projected to be between 232 million to 286 million yuan, with a year-on-year increase of 3.77% to 27.93% [1] - The growth in Jianda Zhixin's 2025 performance is attributed to two main factors: the rapid development of its core business in centralized operation of medical consumables (SPD), which has a high gross profit margin, enhancing overall profitability [1] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing liabilities and reduced financing costs through negotiations with financial institutions, positively impacting net profit [1] Group 2 - Jianda Zhixin primarily engages in the direct sales and distribution of medical devices, providing centralized operation services for medical consumables (SPD) to end hospitals [1] - The company's direct sales and distribution products mainly include vascular interventional devices, surgical instruments, IVD (in vitro diagnostic) products, and medical equipment [1]

Group 1 - The company, Shanghai Jianda Zhixin Medical Technology Group Co., Ltd., has issued a voluntary performance forecast for the fiscal year 2025, indicating that the net profit attributable to shareholders is expected to be positive and show an upward trend [1][3] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the company and the auditors [2] Group 2 - The company's medical consumables centralized operation (SPD) business is experiencing rapid growth, contributing to an increase in overall profitability due to its high gross profit margin [3] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing debt and a reduction in financing costs through negotiations with financial institutions, positively impacting net profit [3]

Group 1 - The company has issued a voluntary performance forecast for the period from January 1, 2025, to December 31, 2025, expecting a positive net profit attributable to shareholders and a positive net profit after deducting non-recurring gains and losses, both showing an upward trend [1] - The preliminary data for the performance forecast has been calculated by the company's finance department and has not yet been audited by an external auditor. There are no discrepancies between the company and the auditing firm regarding this performance forecast [1] - The increase in performance is attributed to the rapid development of the company's centralized operation of medical consumables (SPD) business, which has a high gross profit margin, enhancing the overall profitability of the company. Additionally, the company has optimized its financial structure, reducing interest-bearing debt year-on-year and lowering financing costs through negotiations with financial institutions, positively impacting net profit [1]

Core Viewpoint - The company Jianfa Zhixin (301584.SZ) expects a net profit attributable to shareholders of 242 million to 296 million yuan for 2025, representing a year-on-year growth of 6.00% to 29.65% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between 232 million and 286 million yuan, indicating a year-on-year increase of 3.77% to 27.93% [1] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing debt [1] - Through communication and negotiation with financial institutions, the company has successfully reduced financing costs, leading to a decrease in financial expenses and positively impacting net profit [1] Business Development - The company's medical consumables centralized operation (SPD) business has maintained rapid growth, contributing to a higher gross profit margin and enhancing overall profitability [1]

证券日报网讯1月15日，建发致新（301584）发布2025年度业绩预告称，公司预计2025年度归属于上市 公司股东的净利润为24，200万元—29，600万元，比上年同期增长6.00%—29.65%。 ...

Core Viewpoint - The company Jianfa Zhixin expects a net profit attributable to shareholders of 242 million to 296 million yuan for 2025, representing a year-on-year growth of 6% to 29.65% due to the rapid development of its medical consumables centralized operation (SPD) business, which has a high gross profit margin [1] Group 1 - The company's SPD business is experiencing rapid growth, contributing significantly to overall profitability [1] - The gross profit margin of the SPD business is high, enhancing the company's overall profitability [1] - The company is optimizing its financial structure, resulting in a year-on-year decrease in interest-bearing liabilities [1] Group 2 - The company has engaged in communication and negotiation with financial institutions to reduce financing costs, positively impacting net profit [1] - Financial expenses have decreased year-on-year, further contributing to the increase in net profit [1]